NOVO-VERAMIL TABLET
Страна: Канада
Език: английски
Източник: Health Canada
Данни за продукта
(SPC)
29-05-2013
Понастоящем някои документи за този продукт не са налични, можете да изпратите заявка до нашата служба за клиенти и ние ще ви уведомим веднага щом успеем да ги получим.
Изпрати заяв.
Изпрати заяв.
Активна съставка:
VERAPAMIL HYDROCHLORIDE
Предлага се от:
TEVA CANADA LIMITED
АТС код:
C08DA01
INN (Международно Name):
VERAPAMIL
дозиране:
80MG
Лекарствена форма:
TABLET
Композиция:
VERAPAMIL HYDROCHLORIDE 80MG
Начин на приложение:
ORAL
Броя в опаковка:
100/500/1000
Вид предписание :
Prescription
Терапевтична област:
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Каталог на резюме:
Active ingredient group (AIG) number: 0113846002; AHFS:
Статус Оторизация:
CANCELLED POST MARKET
Дата Оторизация:
2018-05-15
Данни за продукта
PRODUCT MONOGRAPH
PR
NOVO-VERAMIL
(verapamil hydrochloride)
80 mg, 120 mg tablets
Antiarrhythmic/Antianginal/Antihypertensive Agent
PR
NOVO-VERAMIL SR
(verapamil hydrochloride)
240 mg sustained release tablets
Antihypertensive Agent
Teva Canada Limited
Date of Preparation:
30 Novopharm Court
May 28, 2013
Toronto, Ontario
M1B 2K9
Submission Control No: 164741
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................................................
5
ADVERSE REACTIONS
...............................................................................................................
9
DRUG INTERACTIONS
.............................................................................................................
12
DOSAGE AND ADMINISTRATION
.........................................................................................
18
OVERDOSAGE
...........................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
21
STORAGE AND STABILITY
.....................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 26
PART II: SCIENTIFIC INFORMATION
...............................................................................
28
PHARMACEUTICAL INFORMATION
...................................................................................
Прочетете целия документ
